<DOC>
	<DOC>NCT00778921</DOC>
	<brief_summary>This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients with hypertension not adequately controlled with amlodipine alone.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP ≥ 95 mmHg and &lt; 110 mmHg at Visits 1 and 2 Patients who have been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP ≥ 90 mmHg and &lt; 110 mmHg at Visit 2 All patients must have a msDBP ≥ 90 mmHg and &lt; 110 mmHg at Visit 5 (randomization) Severe hypertension Pregnant or nursing (lactating) women Premenopausal women not taking accepted form of birth control Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1 History of cardiovascular conditions Uncontrolled Type 1 or Type 2 diabetes mellitus Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with similar chemical structures Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Aliskiren</keyword>
	<keyword>Amlodipine</keyword>
	<keyword>Non-responder to Amlodipine</keyword>
</DOC>